Metrics as of 10/16/2026, 08:53 AM (Berlin time), refresh in progress.
Enanta Pharmaceuticals Stock
Enanta Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jay R. Luly
- Employees
- 120
- Market cap
- $323 M
- IPO
- 21/03/2013
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV),…
Enanta Pharmaceuticals stock: price history
1D
-3.2%
1W
-11.2%
1M
-12.6%
6M
-20.8%
YTD
-29.6%
1Y
-2.5%
2Y
-8.3%
5Y
-84.5%
10Y
-54.0%
Next earnings date
Next earnings date
16/11/2026 (in 30 days)
Volatility around earnings
~51% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Enanta Pharmaceuticals
Analyst assessment of Enanta Pharmaceuticals
PRICE TARGET LOW
US$20.00
CONSENSUS
US$20.00
MEDIAN
US$20.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
14
BUY
3
HOLD
2
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 23/09/2026
Enanta Pharmaceuticals stock metrics
P/E
-4.61
P/B
3.19
EV/EBITDA
-7.63
RETURN ON EQUITY
-19.3%
NET MARGIN
-135.8%
DEBT/EQUITY
0.55
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.3%
FLOAT SHARES
27,745,089
AVG. DAILY VOLUME (30D)
266,005
Insider transactions (SEC)
Rottinghaus Scott T.
Institutional holders
Comparable stocks
Frequently asked questions about Enanta Pharmaceuticals stock
What does Enanta Pharmaceuticals do?
Enanta Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jay R. Luly, the company employs around 120 people.
The IPO was on 21/03/2013; the stock trades on NASDAQ under the ticker ENTA.
What do analysts say about Enanta Pharmaceuticals stock?
19 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$20.00, ranging from US$20.00 to US$20.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Enanta Pharmaceuticals report next?
The next earnings date is 16/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does Enanta Pharmaceuticals pay a dividend?
No, Enanta Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Enanta Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Enanta Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Enanta Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.